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Abstract: 
Borrelia species fall into two groups, the Borrelia burgdorferi sensu lato 
(Bbsl) complex the cause of Lyme borreliosis (LB; also known as Lyme 
disease LD) and the relapsing fever group. Both groups exhibit inter and 
intraspecies diversity and thus, have variations in both clinical 
presentation and diagnostic approaches. A further layer of complexity is 
derived from the fact that ticks may carry multiple infectious agents and 
are able to transmit them to the host during blood feeding, with potential 
overlapping clinical manifestations. Besides this, pathogens like Borrelia 
have developed strategies to evade the host immune system, which allows 
them to persist within the host, including humans.  
 
Diagnostics can be applied at different times during the clinical course and 
utilise sample types, each with their own advantages and limitations. These 
differing methods should always be considered in conjunction with potential 
exposure and compatible clinical features. Throughout this review, we aim 
to explore different approaches providing the reader with an overview of 
methods appropriate for various situations. This review will cover human 
pathogenic members of Bbsl and relapsing fever borreliae, including newly 
recognised B. miyamotoi spirochetes.  
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	

22 
 species fall into two groups, the  	
 sensu lato (Bbsl) 23 
complex the cause of Lyme borreliosis (LB; also known as Lyme disease LD) and 24 
the relapsing fever group. Both groups exhibit inter8 and intra8species diversity and 25 
thus, have variations in both clinical presentation and diagnostic approaches. A 26 
further layer of complexity is derived from the fact that ticks may carry multiple 27 
infectious agents and are able to transmit them to the host during blood feeding, with 28 
potential overlapping clinical manifestations. Besides this, pathogens like  29 
have developed strategies to evade the host immune system, which allows them to 30 
persist within the host, including humans.  31 
 32 
Diagnostics can be applied at different times during the clinical course and utilise 33 
sample types, each with their own advantages and limitations. These differing 34 
methods should always be considered in conjunction with potential exposure and 35 
compatible clinical features. Throughout this review, we aim to explore different 36 
approaches providing the reader with an overview of methods appropriate for various 37 
situations. This review will cover human pathogenic members of Bbsl and relapsing 38 
fever borreliae, including newly recognised  spirochetes. 39 
 40 







41 
Various methods can be applied to detect the presence of  in vectors. Widely 42 
used approaches that demonstrate significant sensitivity, specificity and reliability 43 
include: multiple formats of PCRs, mostly nested PCR that target different genomic 44 
loci, selection of which depends on the sample origin (template); reverse8line blotting 45 
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(RLB), based on hybridization of amplified selected  genes with spirochete846 
specific probes; multilocus sequences analysis (MLSA) and multilocus sequence 47 
typing (MLST), based on the sequence analysis of amplified fragments of spirochete 48 
genome or microscopy with stained spirochetes in tick midgut or salivary glands 49 
(Aguero8Rosenfeld, et al. 2005, Margos, et al. 2011).  The most recently applied 50 
techniques include next generation sequencing (NGS) and proteomic approaches. 51 
Cultivation of  in commercial BSK (Barbour8Stoenner8Kelly) or home8made 52 
MKP (modified Kelly8 Pettenkoffer) media, that for a long time considered to be a 53 
gold standard in LB diagnostics, is still widely used, but is rather time consuming and 54 
challenging. The culture negative cases do not necessarily mean the absence of 55 
spirochetes in a sample. The failure to culture the spirochetes might be caused by 56 
multiple vector8, spirochete,8 media8 or cultivation conditions related factors (Cerar, 57 
et al., 2008, Ružić8Sabljić, et al. 2014, Rudenko, et al., 2016). Nowadays, the priority 58 
of all used techniques is re8directed form simple detection of pathogen in either 59 
environmental sample or clinical sample, to simultaneous detection and identification 60 
of spirochete species (or possible co8infection agents).  Considering the high 61 
possibility of the presence of multiple pathogens in tick vectors, the other question is 62 
whether to use singleplex or multiplex formats for their detection/identification. Fluidic 63 
microarrays allow the assessment of multiple tick8borne pathogens simultaneously 64 
(Vayssier8Taussat, et al. 2013).  65 
 66 
Use of proteomic methods to detect presence of some relapsing fever in the 67 
hemolymph of ticks provides additional options for borrelial detection in vectors 68 
(Fotso Fotso, et al. 2014). 69 
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These methods provide invaluable research tools and facilitate epidemiological 70 
studies, but their clinical relevance is debatable. Detection of a pathogen in the 71 
vector does not imply that it has been successfully transmitted to the host upon 72 
which the tick has fed. Transmission dynamics are complex and multi factorial and 73 
beyond the scope of this review. Home use diagnostic kits are available and allow 74 
individuals to test collected ticks for the presence of Lyme borreliae. The reliability of 75 
these tests has been highly debated. Tick bites are frequently unnoticed and might 76 
only demonstrate that you have been in a risk environment, but do not necessarily 77 
correlate with any infectious consequences. That is why use of such tests is of 78 
limited value for diagnosis, but can be useful for epidemiological studies. 79 
 80 
Recommendation: 81 
Tick testing as supportive data for identification of LB endemic regions; correct 82 
selection of PCR target based on the final goal of tests and sample nature; re883 
analysis of tested sample targeting different genomic loci; consider the presence of 84 
co8infection with multiple pathogens as highly possible. 85 
 86 




87 
A reliable clinical diagnosis of LB is only evident to the non8expert physician when a 88 
typical erythema migrans (EM) is present (Stanek and Strle 2003). Since the large 89 
majority of LB symptoms have minimal diagnostic value because of their lack of 90 
specificity, diagnosis of LB might be challenging for general practicioners in patients 91 
without EM (Strle and Stanek 2009). Generally there exists a tendency towards 92 
overdiagnosis of chronic Lyme disease (Czupryna, et al. 2016,Koedel, et al. 93 
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2015,Sigal 1996). Although different diagnostic approaches (mentioned later) have 94 
been explored, to date the only recommended supportive tests used are serological 95 
confirmation. Serological results alone are insufficient to distinguish whether the 96 
patient suffers from an acute or re8infection that needs treatment, or is only 97 
seropositive because of a past infection. This might be especially problematic for 98 
individuals that are frequently exposed to ticks and therefore have at high risk of re899 
infection. However even in low risk areas, the positive predictive value of serological 100 
tests can be very low (Lantos, et al. 2015), meaning that clinical manifestations still 101 
remain crucially important criteria for a reliable diagnosis of the disease. Factors that 102 
need to be integrated for a reliable diagnosis are therefore the occurrence of 103 
compatible symptoms, serological results and risk of tick exposure. Figure 1 provides 104 
a diagnostic overview for LB. 105 
 106 

 
 
  
 107 


108 
In cases where EM is clearly evident, serological tests are not needed and treatment 109 
should start immediately (Stanek, et al. 2012). In patients who do not develop EM, 110 
serological tests are recommended to support the diagnosis (Aguero8Rosenfeld, et 111 
al. 2005). Initial problems with the specificity and sensitivity of serological tests have 112 
resulted in controversial statements on their efficacy to support diagnosis of acute 113 
LB. Recently, serological tests have been optimized switching from a single  114 
strain cell extract to a use of combination of more precisely chosen recombinant 115 
antigens or synthetic peptides (Fang Ting, et al. 2000,Goettner, et al. 2005). 116 
Previously a two8tier test approach, in which the presence of antibodies is first tested 117 
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 6
by a highly sensitive ELISA and, in case of a positive result, further confirmed by a 118 
highly specific immunoblot, was recommended (Branda, et al. 2010,Koedel, et al. 119 
2015). Noteworthy, the reported accuracy of ELISAs and immunoblots varies 120 
throughout Europe and a recent study revealed no overall benefit of two8tiered tests 121 
over single tests (Leeflang, et al. 2016). Only early stage patients (symptoms <6 122 
weeks) might still be seronegative, as they have not developed antibodies yet. 123 
Therefore, diagnosis of LB should be re8evaluated in seronegative late stage 124 
patients (Stanek, et al. 2012). Low antibody titers have been observed after antibiotic 125 
treatment indicating that the induced B8cell immune response is probably not very 126 
long8lived and robust. Especially patients where  took longer to disseminate 127 
seem to develop long8lived antibody titers less efficiently (Aguero8Rosenfeld, et al. 128 
1996,Elsner, et al. 2015,Hammers8Berggren, et al. 1994,Nowakowski, et al. 2003). 129 
Recent mouse studies have shown that  have a direct effect on the mouse B8130 
cell response (Elsner, et al. 2015,Elsner, et al. 2015,Hastey, et al. 2012,Hastey, et 131 
al. 2014). However, the underlying mechanism in humans requires further 132 
investigation. Showing the induction of strain specific immunity (not non8133 
crossprotective), mouse and human studies together (Khatchikian, et al. 2014) may 134 
explain reinfection of LB. Consequently, previous  infections must be taken 135 
into account when considering serological testing (Nadelman and Wormser 2007).  136 
 137 
Despite the described improvement of these tests, we still face the problem of non8138 
standardization and inappropriate application of current serological tests (Ang, et al. 139 
2011,Leeflang, et al. 2016,Markowicz, et al. 2015,Muller, et al. 2012). Different (in8140 
house) assays and result interpretation remain a major problem (Fallon, et al. 2014) 141 
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that should be solved in the future by the implementation of a universial and 142 
worldwide (or Europe/USA wide) diagnostic standard test, or as a minimum, use of 143 
internationally agreed standards and participation in quality control schemes. 144 
However, the problem remains (especially amongst high risk groups) to distinguish 145 
between an acute and a resolved infection. Future studies should therefore focus on 146 
the development of new strategies that would allow a yes or no result. 147 
 148 
Noteworthy, serological tests should not be used as a proof of efficacy of the 149 
antibiotic treatment, although antibody titers generally decrease after antibiotic 150 
treatment, however patients may remain seropositive for years after the infection in 151 
the absence of active disease (Aguero8Rosenfeld, et al. 1996,Glatz, et al. 152 
2006,Hammers8Berggren, et al. 1994,Kalish, et al. 2001,Kowalski, et al. 153 
2010,Lomholt, et al. 2000). Instead, the disappearance of symptoms is a more 154 
reliable sign of cure.   155 
 156 
When neuroborreliosis is suspected, detection of intrathecally produced anti8 157 
antibodies significantly supports the diagnosis. However, results might be negative at 158 
early stages and more often in children (Christen, et al. 1993). Measurement of 159 
8specific antibodies in CSF cannot be used to assess the efficiency of 160 
treatment (Koedel, et al. 2015). 161 
 162 
Since antibiotic treatment is generally considered efficient, differential diagnosis is 163 
crucial in case of a chronic course of the disease (Halperin 2015,Halperin 164 
2016,Hjetland, et al. 2015,Markowicz, et al. 2015,Rebman, et al. 2015,Wills, et al. 165 
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2016). A chronic course has been observed in patients infected by , viral and 166 
non8viral pathogens, such as  Epstein8Barr virus (glandular fever), 	
 167 
(Q fever), or Ross River virus (epidemic polyarthritis) (Aucott, et al. 2013,Galbraith, 168 
et al. 2011,Hickie, et al. 2006,Katz and Jason 2013) and the underlying causes are 169 
not clear. In this context, also the general health status and/or the lifestyle of the 170 
patient should be considered. In general, immunocompromised or otherwise not 171 
completely healthy patients might be at higher risk to develop chronic symptoms 172 
after treatment. Patients with hematological malignancies for example seem to suffer 173 
more often from disseminated disease and more frequently require retreatment 174 
(Maraspin, et al. 2015). In non8immunocompromized cases, where symptoms 175 
continue to persist even after appropriate antibiotics treatment, it is currently not 176 
recommended to prolong the treatment. Clinical studies have shown that the risk of 177 
side effects outweighs any potential therapeutic benefits (Klempner, et al. 178 
2001,Koedel, et al. 2015,Krupp, et al. 2003). In these cases, co8infections with other 179 
tick borne diseases or other possible causes of the symptoms should be excluded 180 
(Belongia 2002,Berghoff 2012,Godar, et al. 2015,Swanson, et al. 2006) and 181 
symptomatic treatment considered (Koedel, et al. 2015). Only in late 182 
neuroborreliosis, is prolongation of the antibiotic treatment justifiable in cases of 183 
persistent cerebrospinal fluid (CSF) lymphocytic pleocytosis (Koedel, et al. 2015).  184 
 185 
In rare cases,  can cause problems with the heart and vascular system and 186 
might be considered as underlying cause of stroke8like symptoms in patients which 187 
otherwise have no obvious risk for cardiovascular diseases (Allen and Jungbluth 188 
2016,Zajkowska, et al. 2015). Full description of LB clinical manifestations and their 189 
Page 9 of 36
Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801
Vector-Borne and Zoonotic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only/Not for Distribution
 9
diagnosis have been recently reviewed by Stanek and co8workers (Stanek, et al. 190 
2011). 191 
 192 
When encountering a tick bite, correct and early removal of the tick is a good way to 193 
reduce probability of infection. In Europe, only about 2% (Wilhelmsson, et al. 2016) 194 
and in USA, about 1% (Heymann and Ellis 2012) of patients bitten by a tick develop 195 
LB. Detection of spirochete DNA in ticks alone does not necessarily means the 196 
succesful pathogen transmission, which is why the value of this test has limited 197 
diagnostic value for LB ((ESGBOR) 2013), but is useful for epidemiological studies 198 
(Reye, et al. 2010) to define risk areas.  In this context, next generation sequencing 199 
is a new emerging technique that allows screening of the same tick in parallel for 200 
various tick8borne pathogens, with the potential of getting more detailed information 201 
about co8infections of ticks and identification of new yet unrecognised pathogens 202 
(Michelet, et al. 2014,Vayssier8Taussat, et al. 2013). As transmission of  (and 203 
indeed other pathogens) depends on the length of tick  attachment, measurement of 204 
scutal and coxial indexes can indicate duration of attachment (Crippa, et al. 205 
2002,Gray, et al. 2005,Kahl, et al. 1998,Meiners, et al. 2006,Tijsse8Klasen, et al. 206 
2011). In the absence of an EM and the presence of other LB related symptoms, 207 
seroconversion can be used for supportive diagnosis. However, in the absence of 208 
symptoms, seroconversion is no indication for antibiotic treatment as a study in a 209 
Swiss risk group demonstrated that only 2% of patients who seroconverted 210 
developed clinical LB (Fahrer, et al. 1991). Thus, as tick bite is a poor predictor of 211 
disease, treatment is advisable only upon appearance of LB symptoms.  212 
 213 
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Recommendation: 214 
Clinical diagnosis alone, given a history of potential exposure and presence of EM, 215 
can be sufficient, however clinical interpretation should generally be made in 216 
conjunction with supporting laboratory findings to reach a reliable diagnosis. 217 
 218 

 
 
 
 

  219 

 !"#$%220 
Direct detection of  in the peripheral blood, other body fluids or tissues by 221 
microscopy or molecular methods can be used as strong additional evidence in the 222 
diagnosis of LB, but might have limited significance when used alone (Aguero8223 
Rosenfeld, et al. 2005). The sensitivity of PCR on skin biopsies is significantly higher 224 
than some other molecular tools, however, recognition of the EM itself is the best 225 
diagnosis for LB (Aguero8Rosenfeld, et al. 2005), nevertheless this provides useful 226 
research data regarding strain prevalence, virulence and provides insights into 227 
deciphering pathogenesis of LB (Strle, et al. 2013). Cultivation of  from 228 
patient samples might be an alternative method to detect viable , but is both 229 
time consuming and challenging (Rudenko,  et al. 2016). As such, cultivation is best 230 
reserved as a research tool.  231 
 232 
Lymphocyte transformation tests (LTT) have been explored for their potential to 233 
overcome the diagnostic gap in LB patients without EM but before seroconversion 234 
and in re8infected seropositive patients. This assay measures lymphocyte 235 
proliferation  after stimulation with  	
specific antigens. Currently, 236 
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results are contradictory and consequently LTT is not recommended as a routine 237 
diagnostic tool (Dessau, et al. 2014,Mygland, et al. 2010). T8cell ELISPOT is another 238 
  stimulation assay currently explored and improved (Jin, et al. 2013). More 239 
direct methods measuring peripheral blood levels of specific cell subpopulations 240 
(CD57+ cells (Marques, et al. 2009) or antigen8reactive cells (Tario, et al. 2015) by 241 
flow cytometry, direct measure of CXCL13 levels in the CSF or metabolites within 242 
serum (Molins, et al. 2015) are also not at a point yet to be used reliably for clinical 243 
diagnosis. CD57 cell counts seem not to be reliable as a validation study found no 244 
difference between patients and healthy controls (Marques, et al. 2009). 245 
Demonstration of CSF CXCL13 as an activation marker is not specific for LB, its 246 
absence is believed to have some value in excluding neuroborreliosis (Rupprecht, et 247 
al. 2014) and it might become a valuable supportive tool to estimate treatment 248 
efficiency in case of neuroborreliosis (Koedel, et al. 2015,Schmidt, et al. 2011,Senel, 249 
et al. 2010). Problems with HLA types and identification of epitopes for antigen8250 
specific T8cell staining are challenges that need to be addressed to validate the 251 
potential of  specific T8cell counts in peripheral blood to support diagnosis of 252 
LB. Metabolite measurement is a future strategy under investigation but needs 253 
further validation. 254 
 255 
Generally, the detection of  DNA within ticks as well as other methods 256 
discussed above should be considered as valuable research tools providing useful 257 
information about the epidemiology of tick8borne diseases in general and LB 258 
particularly. As with serological methods, their value is lower when used alone. 259 
Combination of diagnostics, clinical and molecular tests provides a more robust and 260 
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timely diagnosis of disease. In any case, interpretation of tests results and clinical 261 
diagnosis of LB remains controversial and should currently be restricted to experts. 262 
 263 
Development and application of new molecular tools allow the detection and 264 
differentiation among Lyme borreliosis or relapsing fever spirochetes, clearly 265 
separating  	
 sensu lato spirochetes from recently described 266 
 (Margos, et al. 2008,Rudenko, et al. 2009,Venczel, et al. 2015). 267 
Combination of multilocus PCR with electro spray ionisation and mass spectrometry 268 
has recently been investigated for the detection and genotyping of  species 269 
in whole blood (Eshoo, et al. 2012). 270 
 271 
Recommendation:  272 
These tests are valuable research tools providing useful information about the 273 
patient’s immune response, but interpretation for clinical diagnosis has not been 274 
clearly shown and should currently be restricted to specialised laboratories.  275 
 276 


	

277 
Veterinary infections are less well documented and benefit from laboratory 278 
confirmation to ensure correct diagnosis. This is particularly important as EM lesions 279 
have not been reported in animals and clinical signs are often common to several 280 
pathologies. As for human cases, serology is the primary diagnostic approach used, 281 
sometimes supported by use of PCR. Despite the absence of EM, cardiac, 282 
neurological signs and lameness have been reported amongst companion animals 283 
(Agudelo, et al. 2011,Hovius, et al. 1999,Krupka and Straubinger 2010). Most 284 
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veterinary cases have focussed upon lameness in dogs with positive serology, 285 
though this does not necessarily establish borrelial causality for this condition. Rapid 286 
immunochormatographic tests are often used in veterinary private practice to aid 287 
diagnosis, however these assays have not necessarily undergone the rigorous 288 
quality control applied to human serodiagnostic tests (Savić, et al. 2010). 289 
 290 
&
'291 
292 
In general, the clinical presentation of relapsing fever borreliosis is significantly 293 
distinct from that of LB. The possible exception to this being the appearance of a 294 
skin rash that challenges the previously believed “pathognomonic” EM, caused by 295 
the borrelial agent carried by 	 
 ticks in the United States, 296 
known as STARI (Borchers, et al. 2015,Masters, et al. 2008).   297 
 298 
Human infection by recently described   usually results in fever and 299 
associated flu8like signs (headache, chills, fatigue, myalgia), occasionally with 300 
neurological complications such as meningoencephalitis (Fonville, et al. 301 
2014,Krause, et al. 2015).  302 
 303 
Relapsing fever, as its name suggests, results in relapsing febrile episodes 304 
interspersed by afebrile periods. This is often accompanied by jaundice, muscle 305 
pain, headaches and sometimes involvement of major organs (Borgnolo, et al. 306 
1993). This clinical picture can often be mistaken for other infections such as malaria 307 
that tend to overlap geographically in many endemic regions (Lundqvist, et al. 2010). 308 
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 309 
	310 

311 
Though for LB, microscopy is not suitably sensitive for detection, this has been the 312 
diagnostic gold standard for detection of many relapsing fever spirochetes. Darkfield 313 
examination of unstained wet8preparations, Giemsa or silver8stained blood or tissue 314 
sections, or immunofluroescence methods have been successfully used. Despite its 315 
frequent use, even relapsing fever can be difficult to detect using microscopy with 316 
some species such as  
 typically producing lower blood burdens than 317 
others, like  
. For such cases, a centrifugation step to concentrate the 318 
sample can be beneficial (Larsson and Bergström 2008). Furthermore, detection is 319 
restricted to times of febrile episodes when spirochetes are present at detectable 320 
levels. On a cautionary note, various artefacts can share the size and helical shape 321 
of spirochetes when viewed by darkfield microscopy, but tend not to show the typical 322 
gyrating spirochete8characteristic movement. Microscopy will not provide information 323 
regarding the infecting species. 324 
 325 
Recommendation: 326 
Microscopic methods lack both sensitivity and specificity, but can add value when 327 
used in conjunction with other methods. Sample concentration can offer distinct 328 
benefits. 329 
 330 
331 
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Cultivation methods for detection of  have been particularly challenging and 332 
some members of the genus being particularly refractory to cultivation (Cutler, et al. 333 
1994) whilst others are cultivable, but only in complex medium. Huge advances were 334 
made with the formulation of BSK medium with a commercial variant BSK8H 335 
supporting the growth of LB strains (Barbour 1984). Relapsing fever strains appear 336 
more diverse in their requirements.  for instance appears to prefer 337 
MKP medium (Wagemakers, et al. 2014) or high serum concentrations (Margos, et 338 
al. 2015). On a cautionary note, these preferences might reflect batch variations of 339 
composite ingredients that can vastly influence performance of these “home8made” 340 
media (Cutler personal observation). Collectively, cultivation should be considered a 341 
low yield procedure, but vital for recovery of much8needed strains for research 342 
purposes (Ružić8Sabljić, et al. 2014). 343 
 344 
Animal inoculation or xenodiagnosis (allowing infected ticks to feed upon a test 345 
animal) has been used for primary recovery of isolates prior to cultivation in axenic 346 
medium (Naddaf, et al. 2015,Schwan, et al. 2012). It must be remembered that some 347 
species are refractory to growth in most animal models, such as 
. 348 
 349 
Recommendation: 350 
Cultivation is low yield, time consuming and expensive and thus poorly suited to 351 
support diagnosis. Nevertheless, it still has a vital role for recovery of isolates for 352 
research purposes. 353 
 354 
355 
Page 16 of 36
Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801
Vector-Borne and Zoonotic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only/Not for Distribution
 16
For the relapsing fever group, specific serology can be undertaken using GlpQ 356 
protein as antigen. GlpQ is absent from LB species, thus facilitating it’s specificity for 357 
diagnostic purposes (Fritz, et al. 2013). Alternatively, BipA can also serve as a 358 
differential antigen present in relapsing fever spirochetes, but absent from the LB 359 
group (Lopez, et al. 2010). As acutely presenting patients may not yet have had 360 
sufficient time for seroconversion, serology is best reserved for retrospective 361 
diagnosis. 362 
 363 
(&364 
PCR provides a valuable diagnostic approach in acutely ill patients (Mediannikov, et 365 
al. 2014). This overcomes the poor sensitivity of microscopy and can either be used 366 
to diagnose relapsing fever borreliosis, or to further characterise the infecting 367 
spirochete. The absence of  in LB species makes it a specific target for 368 
detection of relapsing fever spirochetes (Takano, et al. 2014). Other assays can 369 
either speciate specific relapsing fever borreliae or be designed to detect a single 370 
member of the relapsing fever clade such as  (Elbir, et al. 2013,Reiter, 371 
et al. 2015). The limitation of this approach is having an appropriate sample that is 372 
likely to contain spirochetal DNA. Blood collected during febrile episodes and CSF 373 
samples have given good results (Gugliotta, et al. 2013). Furthermore, in highly 374 
relapsing fever endemic areas, it is possible to have positive PCR results unrelated 375 
to current clinical pathology (Cutler, et al. 2010). 376 
 377 
Recommendation: 378 
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PCR can provide useful supporting information, but multiple available assays must 379 
be properly standardised, and are hampered by sample timing, type and quality.  380 
381 
)*
+,382 
NGS offers huge potential and data has only recently been forthcoming limiting 383 
comprehensive appraisal at this stage. With the exception of dermato8borreliosis, 384 
here the challenge is which diagnostic sample type to investigate for LB in the 385 
absence of focal lesions. Sensitivity can be further improved, especially amongst 386 
high levels of host DNA. Care should be taken to avoid bias when using target 387 
enhancement strategies to amplify low copy number targets. Data analysis 388 
represents an additional computational challenge. NGS methods combined with 389 
bioinformatics tools might overcome the limitations of culture8connected techniques 390 
or of some molecular protocols. However, the extreme diversity of spirochetes from 391 
 	
 sensu lato complex reduce the usefulness of NGS as it doesn’t 392 
differentiate between the pathogenic to human spirochete strains from those that 393 
were never connected with human LB. Additionally this offers a means of assessing 394 
rank abundance, evolving genomic profiles such as those corresponding to vector 395 
adaptations (Gatzmann, et al. 2015) and fluctuations over time providing valuable 396 
insights into host8microbial interactions (Strandh and Råberg 2015).  397 
 398 
To date enrichment techniques can only partially overcome sensitivity problems 399 
caused by the giant excess of host DNA (vector, endosymbiont and other microbial 400 
DNA) compared to the low proportion of target DNA (borrelial DNA in ticks is <0.01% 401 
of total DNA within field8collected nymphal ticks) (Carpi, et al. 2015). This can impact 402 
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upon successful detection with only about a third of infected ticks revealing positive 403 
 NGS data (Carpi, et al. 2015).  404 
 405 
Recommendations: 406 
NGS offers huge potential and data has only recently been forthcoming limiting 407 
comprehensive appraisal at this stage. Sensitivity can be further improved, 408 
especially amongst high levels of host DNA. Care should be taken to avoid bias 409 
when using target enhancement strategies to amplify low copy number targets. Data 410 
analysis represents an additional computational challenge. 411 
 412 
-

413 
Several excellent fact sheets have been produced by ECDC to provide information 414 
on LB and tick8borne relapsing fever. Furthermore, more specific resources can be 415 
obtained from European study group for Lyme borreliosis (ESGBOR; 416 
www.escmid.org/research_projects/study_groups/esgbor/). 417 
 418 
./

419 
The poor sensitivity of direct detection methods coupled with the poor predictive 420 
value of indirect serological methods, particularly in less typical clinical 421 
presentations, presents a significant diagnostic challenge. Serology is further 422 
challenged by the requirement for sufficient time in order for the host to produce 423 
antibody responses to enable detection. Detection of the host response to infections 424 
provides a particularly attractive prospect for LB where organism loads are typically 425 
low. Indeed, levels of CXCL13 have shown promise for neuroborreliosis, but require 426 
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further validation (Schmidt, et al. 2011,Senel, et al. 2010). It is possible that 427 
signature biomarker profiles might have value, but whether this would vary too much 428 
between individuals or indeed with differing genetic variants of borreliae awaits 429 
investigation. Another diagnostic approach under exploration is based on targeted 430 
proteomics. By selected reaction monitoring mass spectrometry, specific  431 
proteins can be detected and quantified in skin biopsies (Schnell, et al. 2015). The 432 
powerful new emerging technologies provide insights into our understanding of the 433 
dynamic interactions of borreliae with their vector, host and other organisms, with the 434 
possibility of disclosing opportunities for future intervention. 435 
 436 


0437 
During these brief guidelines, we have attempted to highlight the strengths and 438 
limitations of various diagnostic methods used to diagnose borrelial infection. No 439 
single approach is suitably robust for this purpose, thus making interpretation 440 
challenging. Furthermore, laboratory diagnostics need to be viewed in conjunction 441 
with potential exposure and compatible clinical features. 442 
 443 
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recommended only in case of 
development of symptoms 
Erythema migrans (1) Tick bite (4) Lyme disease symptoms 
Symptoms strongly 
associated with Lyme 
disease (8) 
Symptoms 
Correlation between 
Timepoint of (probable) 
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timepoint of appearance 
of symptoms & 
serological result (5) 
Neuroborreliosis (CSF 
analysis) 
Symptoms disappeared after treatment Remaining symptoms after treatment (6) 
 
Disease manifestations were probably due to Lyme 
disease and the patient can be considered healthy 
again 
Further antibiotic treatment is currently not 
recommended and symptomatic treatment should 
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(2) (3) 
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Differential diagnosis: 
Exclude all other possible 
diseases or causes of 
symptoms 
?????????????
???????????????????????????????????????????????????????????????????
??????????????????????????????????
?
?
?
?
?
?
?
?
?
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
For Peer Review Only/Not for Distribution
 	 
           
 
 !    	   	 

   	  
    
   


	

	
  !"   #    $
      #    
 	 
    "    

  " 
 	 	

%
   	    
   
  
  &'( 	  )	
   &*+("" ' 
	  , - 
   ! 
   (
  +           


	 !

 	  
 	   	  
 
 	 .    	   /
		
	0
		

",&*+.""
0

 	 	  	   	   


-
	1
2
32
			320
 	 0 3 ) 
      
  
Page 35 of 36
Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801
Vector-Borne and Zoonotic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only/Not for Distribution
3)34

0	

	"3#%"
  	 	   	   '   0

     	 	  0 0
%0
	-	
			0		!&*+("$	
  
        0 	   
0  	   0    		
       5    &**&"  

6+778"

  	  0 	      	

          0   /
    

"    
9	   &*+*" :  ); &*+&" :   &*+<"
)0 
     
   		
 


		
	


)	
    &*+(" 0     
 % :
			

	/	
4&*+."=9
&**>"6&*+<"	

 &  	 	
	
 	    	    
 ,    &*+." ! 
       
         	 
Page 36 of 36
Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801
Vector-Borne and Zoonotic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only/Not for Distribution
   
 	      	 


'!
0

	
   	 
 
   	 	 	    	 
(%0
00		1


	4&*+&6&*+."
 
 
Page 37 of 36
Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801
Vector-Borne and Zoonotic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
